Zacks Research Has Optimistic Outlook of VRTX Q1 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Stock analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a research note issued on Monday, March 3rd. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will earn $3.61 per share for the quarter, up from their previous forecast of $3.51. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.70 EPS, Q3 2025 earnings at $3.90 EPS, Q4 2025 earnings at $4.01 EPS, FY2025 earnings at $15.22 EPS, Q1 2026 earnings at $3.82 EPS, Q2 2026 earnings at $3.95 EPS, Q4 2026 earnings at $4.29 EPS and FY2026 earnings at $16.18 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%.

A number of other analysts have also weighed in on the company. Citigroup started coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $575.00 target price for the company. Scotiabank upped their target price on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a “sector perform” rating in a report on Tuesday, February 11th. StockNews.com lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 19th. Wells Fargo & Company lowered Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price objective for the company. in a report on Thursday, January 30th. Finally, Truist Financial increased their price objective on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $506.70.

Vertex Pharmaceuticals Stock Down 1.2 %

Vertex Pharmaceuticals stock opened at $485.72 on Thursday. The business has a fifty day moving average of $446.68 and a two-hundred day moving average of $461.50. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The firm has a market cap of $124.73 billion, a P/E ratio of -220.78, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88.

Insider Activity

In other news, EVP Ourania Tatsis sold 530 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the sale, the executive vice president now directly owns 58,539 shares in the company, valued at $27,825,928.26. This trade represents a 0.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 1,084 shares of company stock worth $505,512 in the last ninety days. Company insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Dunhill Financial LLC grew its position in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares during the period. Legacy Investment Solutions LLC purchased a new position in Vertex Pharmaceuticals in the 3rd quarter valued at about $33,000. Brown Lisle Cummings Inc. purchased a new position in Vertex Pharmaceuticals in the 4th quarter valued at about $30,000. Truvestments Capital LLC purchased a new position in Vertex Pharmaceuticals in the 3rd quarter valued at about $35,000. Finally, Capital Performance Advisors LLP purchased a new position in Vertex Pharmaceuticals in the 3rd quarter valued at about $39,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.